bioAffinity Technologies Secures Mexican Patent Allowance for Lung Cancer Detection Technology
Summary
bioAffinity Technologies announced a patent allowance in Mexico for its CyPath® Lung diagnostic technology, strengthening its global intellectual property protection for early lung cancer detection.
Key Events
-
Mexican Patent Allowance Received
bioAffinity Technologies received notification of allowance from the Mexican Institute of Industrial Property for a patent application related to methods of predicting lung cancer using flow cytometry.
-
Strengthens CyPath® Lung IP
The patent expands global intellectual property protection for the company's commercially available CyPath® Lung diagnostic test, which utilizes flow cytometry and artificial intelligence for early lung cancer detection.
-
Supports Shareholder Value
Management emphasized that strong intellectual property protection for CyPath® Lung benefits patients, physicians, and supports value creation for shareholders, which is critical given the company's current financial position.
Analysis
This patent allowance in Mexico strengthens bioAffinity Technologies' intellectual property portfolio for its CyPath® Lung diagnostic test. For a company facing significant financial challenges and a short cash runway, expanding global IP protection for its core commercial product is a positive development that enhances the long-term value of its assets and could support future strategic initiatives or financing efforts.
At the time of this filing, BIAF was trading at $1.74 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $7.5M. The 52-week trading range was $0.69 to $15.00. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.